Media

Vitalis to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Tuesday, September 1st, 2020 8:00 am ET

NEW YORK, Sept. 1, 2020 (GLOBE NEWSWIRE) -- Vitalis LLC, a specialty pharmaceutical company leveraging its proprietary VTS platform to overcome the limitations of existing drugs and enhance patient experience across a variety of therapeutic areas including multiple sclerosis and post-operative pain, today announced Joseph Habboushe, M.D., MBA., Chief Executive Officer and founder, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 3:00 p.m. Eastern Time.


A live audio webcast of the presentation can be accessed through the Media section of the Company's website at https://www.vitalispharma.com/. A replay of the webcast will be available on the Company's website following the live presentation.

 

About Vitalis:

Vitalis is a privately-held specialty pharmaceutical company focused on overcoming the limitations of existing drugs using its proprietary VTS-Aspirin platform. Its most advanced product, VTS-72, uniquely combines aspirin with fumaric acid, the leading multiple sclerosis medication, to reduce its most common side effect while improving pharmacokinetics. Similarly, its second candidate, VTS-K, may be the first oral ketamine to enter the market, aiming to reduce opioid need while supplanting injectable blood thinners after joint replacements. For additional information, please visit www.vitalispharma.com.

Contact:

Burns McClellan for Vitalis Pharmaceuticals
Lee Roth (Investors) / Ryo Imai (Media)
212-213-0006
lroth@burnsmc.com / rimai@burnsmc.com

© 2019 Vitalis, LLC

All Rights Reserved.

New York, NY

admin@vitalispharma.com